Movement assessment of breast and organ-at-risks using free-breathing, self-gating 4D magnetic resonance imaging workflow for breast cancer radiation therapy.

Motion management is essential in treatment planning of radiotherapy for breast cancer. This study assessed the movement of organs-at-risk and the breast using 4D magnetic resonance imaging (MRI). A self-gating respiration-resolved radial 3D gradient echo sequence was used. Five healthy volunteers were imaged at 1.5 T during free-breathing in supine position making use of a breast board. Median distances between heart and chest wall in axial views were 2.4 cm (range: 1.5 cm) and 3.0 cm (range: 1.7 cm) for end-of-exhale and end-of-inhale. 4D-MRI allowed organ delineation and might be a promising addition to novel RT planning for breast cancer patients.

Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery.

Objective.In MRI-based radiation therapy planning, mitigating patient-specific distortion with standard high bandwidth scans can result in unnecessary sacrifices of signal to noise ratio. This study investigates a technique for distortion detection and mitigation on a patient specific basis.Approach.Fast B0 mapping was performed using a previously developed technique for high-resolution, large dynamic range field mapping without the need for phase unwrapping algorithms. A phantom study was performed to validate the method. Distortion mitigation was validated by reducing geometric distortion with increased acquisition bandwidth and confirmed by both the B0 mapping technique and manual measurements. Images and contours from 25 brain stereotactic radiosurgery patients and 95 targets were analyzed to estimate the range of geometric distortions expected in the brain and to estimate bandwidth required to keep all treatment targets within the ±0.5 mm iso-distortion contour.Main Results.The phantom study showed, at 3 T, the technique can measure distortions with a mean absolute error of 0.12 mm (0.18 ppm), and a maximum error of 0.37 mm (0.6 ppm). For image acquisition at 3 T and 1.0 mm resolution, mean absolute distortion under 0.5 mm in patients required bandwidths from 109 to 200 Hz px-1for patients with the least and most distortion, respectively. Maximum absolute distortion under 0.5 mm required bandwidths from 120 to 390 Hz px-1.Significance.The method for B0 mapping was shown to be valid and may be applied to assess distortion clinically. Future work will adapt the readout bandwidth to prospectively mitigate distortion with the goal to improve radiosurgery treatment outcomes by reducing healthy tissue exposure.

Gadofluorine m uptake in stem cells as a new magnetic resonance imaging tracking method: an in vitro and in vivo study.

OBJECTIVES: Cell tracking using ultrasmall iron particles is well established in magnetic resonance imaging (MRI). However, in experimental models, intrinsic iron signals derived from erythrocytes mask the labeled cells. Therefore, we evaluated Gadofluorine M with other gadolinium chelates for a T1-weighted positive enhancement for cell tracking in vitro. In addition, Gadofluorine M was tested in vivo. MATERIAL AND METHODS: Gadofluorine M and other gadolinium chelates were used to label stem cells with and without uptake-mediating agents in vitro and in vivo using a 1.5 T MRI. In addition, histology and molecular modeling was investigated. RESULTS: Gadofluorine M revealed comparable properties to an uptake mediating agent in molecular modeling. Without an uptake-mediating agent Gadofluorine M-labeled cells were detected as a T1-weighted positive contrast in vitro and in vivo. Histology confirmed a 100% success rate for intracellular labeling. CONCLUSION: This study describes a novel contrast agent with the capability of intracellular accumulation without an uptake mediator providing a T1-positive MRI signal at 1.5 T and may be suitable for cell tracking in animal models with intraparenchymal hemorrhages such as stroke or malignant tumors.

Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

RATIONALE AND OBJECTIVES: To characterize and compare commercially available contrast media (CM) for magnetic resonance imaging (MRI) in terms of their relaxivity at magnetic field strengths ranging from 0.47 T to 4.7 T at physiological temperatures in water and in plasma. Relaxivities also were quantified in whole blood at 1.5 T. METHODS: Relaxivities of MRI-CM were determined by nuclear magnetic resonance (NMR) spectroscopy at 0.47 T and MRI phantom measurements at 1.5 T, 3 T, and 4.7 T, respectively. Both longitudinal (T1) and transverse relaxation times (T2) were measured by appropriate spin-echo sequences. Nuclear magnetic resonance dispersion (NMRD) profiles were also determined for all agents in water and in plasma. RESULTS: Significant dependencies of relaxivities on the field strength and solvents were quantified. Protein binding leads to both increased field strength and solvent dependencies and hence to significantly altered T1 relaxivity values at higher magnetic field strengths. CONCLUSIONS: Awareness of the field strength and solvent associated with relaxivity data is crucial for the comparison and evaluation of relaxivity values. Data observed at 0.47 T can thus be misleading and should be replaced by relaxivities measured at 1.5 T and at 3 T in plasma at physiological temperature.

Time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the chest: combination of parallel imaging with view sharing (TREAT).

RATIONALE AND OBJECTIVES: In view sharing, some parts of k-space are updated more often than others, leading to an effective shortening of the total acquisition time. Undersampling of high-frequency k-space data, however, can result in artifacts at the edges of blood vessels, especially during the rapid signal intensity changes. The objective of this study was to evaluate a new time-resolved echo-shared angiographic technique (TREAT) combining parallel imaging with view sharing. First, the presence of artifacts arising from different temporal interpolation schemes was evaluated in simulations of the point spread function. Second, the image quality and presence of artifacts of time-resolved parallel three-dimensional magnetic resonance angiography (3D MRA) of the chest, acquired with and without view sharing, was assessed in a clinical study of patients with cardiovascular or pulmonary disease. MATERIALS AND METHODS: Using parameters from a time-resolved parallel 3D MRA sequence without view sharing (parallel MRA), giving a 33% increase in spatial resolution, our simulations have revealed that k-space segmentation in 3 regions provides acceptable artifacts. Thirty-six consecutive patients (mean age, 50 +/- 16 years; 15 females, 22 males) were examined in a clinical study with TREAT. The image data were compared with that of a group of 31 consecutive patients (mean age, 46 +/- 19 years; 12 females, 19 males) examined with a conventional time-resolved parallel MRA sequence without view sharing (parallel MRA). The image quality and presence of artifacts was assessed in a blind comparison by 2 radiologists in consensus using MPR and MIP reconstructions. Furthermore, the peak SNR of the pulmonary artery and aorta was compared between both MRA sequences. RESULTS: The image quality of TREAT was rated significantly higher than that of the parallel MRA sequence without view sharing: depending on the orientation of MPR and MIP reconstructions, an excellent image quality was found in 69-89% with TREAT and in 45-71% with the parallel MRA protocol without view sharing, respectively. The presence of artifacts was equal with both sequences. CONCLUSION: View sharing can be successfully combined with other acceleration techniques, such as parallel imaging. TREAT allows the assessment of the thoracic vasculature with a high temporal and spatial resolution.

Effects of injection rate and dose on image quality in time-resolved magnetic resonance angiography (MRA) by using 1.0M contrast agents.

In time-resolved MRA (TR MRA), injection parameters and contrast agent (CA) dose are important factors influencing image quality. In this study, three different injection schemes with different CA volumes were evaluated in 12 healthy volunteers. Injection rates between 0.2 and 0.8 ml/s were evaluated with CA volumes of 10 and 20 ml. To measure circulatory parameters, cine cardiac MRI was performed before each exam. Spatial resolution could be reduced to 2 x 1.4 x 2 mm3, temporal resolution was 2.25 s/frame. To exclude signal saturation at high CA concentrations, a phantom with fixed CA concentrations was placed in the field of view. SNR was measured, and the area under the curve of the arterial signal of the different injection schemes was calculated. Results showed the largest diagnostic window at a relatively slow injection rate of 0.4 ml/s and a CA volume of 10 ml. Circulatory parameters have an important impact on CA arrival, so delay times have to be set depending on these parameters.

Whole-body MR angiography using a novel 32-receiving-channel MR system with surface coil technology: first clinical experience.

PURPOSE: To demonstrate the feasibility of detecting atherosclerotic vascular disease using an innovative magnetic resonance angiography (MRA) protocol in combination with a dedicated whole-body MR scanner with new surface coil technology. MATERIALS AND METHODS: A total of 10 volunteers and eight patients with peripheral arterial occlusive disease (PAOD) were examined at 1.5 T. Conventional digital subtraction angiography (DSA) of the symptomatic region was available as a reference standard in all eight patients. Depending on subjects' size, four to five three-dimensional data sets were acquired using an adapted injection protocol. Images were assessed independently by two readers for vascular pathology. Additionally, signal-to-noise ratios (SNRs) and contrast-to-noise ratios (CNRs) were measured. RESULTS: Whole-body MRA yielded excellent sensitivity and specificity of more than 95% for both readers with high interobserver agreement (k = 0.93). Surface coil signal reception rendered a high SNR (mean 151.28 +/- 54.04) and CNR (mean 120.75 +/- 46.47). Despite lower SNR and CNR of the cranial and cervical vessels, a two-step injection protocol exhibited less venous superposition and therefore proved to be superior compared to single-bolus injection. CONCLUSION: Our approach provides accurate noninvasive high-resolution imaging of systemic atherosclerotic disease, covering the arterial vasculature from intracranial arteries to distal runoff vessels. The recently introduced MR scanner and coil technology is feasible to significantly increase the performance of whole-body MRA.

Peripheral vessels: MR angiography with dedicated phased-array coil with large-field-of-view adapter feasibility study.

At magnetic resonance (MR) angiography with conventional phased-array coils, visualization of the vascular tree from the infrarenal aorta to the pedal arch is not possible in most patients. For this purpose, the authors developed a dedicated adapter with a large field of view that allows coverage of a body length of approximately 1,380 mm. Among five patients with peripheral arteriosclerotic disease, four underwent both conventional angiography and MR angiography. One hundred fourteen vascular segments from the infrarenal aorta to the feet were evaluated. Agreement between findings at conventional angiography and those at MR angiography was 94.7% (108 of 114) for all segments (96.1% [25 of 26] in the abdomen or pelvis, 97.5% [39 of 40] in the thigh, and 91.7% [44 of 48] in the calf or foot).

Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine.

PURPOSE: To compare intraindividually gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for multi-station MR Angiography of the run-off vessels. MATERIALS AND METHODS: Twenty-one randomized healthy volunteers received either Gd-BOPTA or Gd-DTPA as a first injection and then the other agent as a second injection after a minimum interval of 6 days. Each agent was administered at a dose of 0.1 mmol/kg bodyweight followed by a 25-mL saline flush at a single constant flow rate of 0.8 mL/second. Images were acquired sequentially at the level of the pelvis, thigh, and calf using a fast three-dimensional (3D) gradient echo sequence. Source, subtracted source, maximum intensity projection (MIP), and subtracted MIP image sets from each examination were evaluated quantitatively and qualitatively on a segmental basis involving nine vascular segments. RESULTS: Significantly (P < 0.05) higher signal-to-noise and contrast-to-noise ratios were noted for Gd-BOPTA compared to Gd-DTPA, with the more pronounced differences evident in the more distal vessels. Qualitative assessmentrevealed no differences in the abdominal vasculature, a preference for Gd-BOPTA in the pelvic vasculature, and markedly better performance for Gd-BOPTA in the femoral and tibial vasculature. Summation of individual diagnostic quality scores for each segment revealed a significantly (P = 0.0001) better performance for Gd-BOPTA compared to Gd-DTPA. CONCLUSION: Greater vascular enhancement of the run-off vasculature is obtained after Gd-BOPTA, particularly in the smaller more distal vessels. Enhancement differences are not merely dose dependent, but may be due to different vascular enhancement characteristics of the agents.